Poria in Fuling Zexie decoction for treating metabolic dysfunction-associated steatotic liver disease: Underlying mechanisms and key bioactive substances

Figure 3 Integrated analysis of Fuling Zexie decoction/Fuling Zexie decoction without Poria components and metabolomics. A: Venn diagram of anti-metabolic dysfunction-associated steatotic liver disease targets of Fuling Zexie decoction (FZD)-derived components and FZD-regulated metabolic pathway targets; B: Venn diagram of anti-metabolic dysfunction-associated steatotic liver disease targets of Zexie decoction (ZD)-derived components and ZD-regulated metabolic pathway targets; C: Component-target-pathway-metabolite network of FZD; D: Component-target-pathway-metabolite network of ZD; E: Component-target-pathway-metabolite network of 17 targets specifically-regulated by FZD; F: Molecular docking between key components and core targets. MASLD: Metabolic dysfunction-associated steatotic liver disease; FZD: Fuling Zexie decoction without Poria; ZD: Fuling Zexie decoction without Poria; PIK3CB: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.